Dephosphorylation of the RB protein has been reported to be associated with apoptosis. In contrast, we show that treatment of HL60 cells with etoposide or cytosine arabinoside or treatment of breast epithelial cells with a-FAS is associated with the cleavage of a 5 kDa fragment from the C-terminus of RB, resulting in a truncated product that we have designated as p100cl. This cleavage event coincides with the activation of cysteine proteases at the onset of apoptosis, is blocked by the addition of iodoacetamide to cells prior to the onset of apoptosis, and results in the expression of faster migrating protein species which can mimic dephosphorylated RB. The free 5 kDa fragment is detected only during apoptosis, predicts a cleavage site that we have mapped to a unique CPP32-like recognition sequence which is present at the C-terminus of all reported RB homologues, and results in a truncated RB protein with enhanced E2F binding anity. While the causality for this cleavage event in the apoptotic process is still under investigation, our ®ndings suggest distinct post-translational pathways for the RB product between cells examined during growth arrest (p105 hypophosphorylated RB) or apoptosis (p100cl).
Dephosphorylation of the RB protein has been reported to be associated with apoptosis. In contrast, we show that treatment of HL60 cells with etoposide or cytosine arabinoside or treatment of breast epithelial cells with a-FAS is associated with the cleavage of a 5 kDa fragment from the C-terminus of RB, resulting in a truncated product that we have designated as p100cl. This cleavage event coincides with the activation of cysteine proteases at the onset of apoptosis, is blocked by the addition of iodoacetamide to cells prior to the onset of apoptosis, and results in the expression of faster migrating protein species which can mimic dephosphorylated RB. The free 5 kDa fragment is detected only during apoptosis, predicts a cleavage site that we have mapped to a unique CPP32-like recognition sequence which is present at the C-terminus of all reported RB homologues, and results in a truncated RB protein with enhanced E2F binding anity. While the causality for this cleavage event in the apoptotic process is still under investigation, our ®ndings suggest distinct post-translational pathways for the RB product between cells examined during growth arrest (p105 hypophosphorylated RB) or apoptosis (p100cl).
Keywords: apoptosis; chemotherapy; cysteine protease; FAS; retinoblastoma protein A working model for the RB tumor suppressor pathway proposes that the phosphorylation state of the RB protein serves as a thermostat which allows for a conformational tilt that either facilitates (hypophosphorylated state) or inhibits (hyperphosphorylated state) the ability of RB to non-covalently bind to a group of viral or cellular proteins (Ludlow et al., 1989; Weinberg, 1995) . The best characterized RB (`pocket') cellular binding partner is the E2F/DP heterodimeric complex which can function to repress or activate the coordinated transcription of a set of genes required for DNA synthesis depending, respectively, on whether it is bound to or free from RB (Nevins, 1992; Weintraub et al., 1992) . In addition to changes in the phosphorylation state of the full length RB protein, however, we have been studying other post-translational events involving RB. For example, investigators have recently reported that during apoptosis the RB protein undergoes rapid dephosphorylation which is followed by a cleavage event near the N-terminus of RB resulting in the expression of a truncated p68 species (Bing and Dou, 1996) . Although it was suggested that this cleavage event was catalyzed by an ICE-like protease, no consensus cleavage recognition sequence was identi®ed. In contrast, we have determined that a single 5 kDa fragment is cleaved from the C-terminus of RB during either drug-mediated or a-FAS induced apoptosis in human cells derived from dierent lineages. This C-terminal cleavage: (i) coincides with the onset of apoptosis; (ii) is inhibited by iodoacetamide; (iii) maps to an amino acid sequence at RB residue no. 886 which is a consensus substrate for a CED3/CPP32b-like cysteine protease iv) mimics the migration pattern of hypophosphorylated RB and (v) results in a truncated RB with enhanced binding anity to E2F family members.
A truncated (p68) RB species is detected in selected protein lysates and is independent of apoptosis Using protein immunoblot analysis, we have frequently observed a signal at approximately 68 kDa which is coexpressed with full length p110 RB in selected tumor cell lines using dierent commercially available a-RB monoclonal antibodies (Figure 1a ). In addition, we had observed that the detection of this p68 signal was independent of apoptosis and its presence appeared to be more closely related to the speci®c cell line tested. To con®rm that this lower p68 product originated from the Rb gene, we constructed a series of RB/chimera constructs for transfection into an RB (7/7) lung tumor line, H2009 (Kratzke et al., 1993) . Transfections were performed with either the parental expression vector, wildtype RB, a full-length missense mutant RB (706F) (Kaye et al., 1990) , or a set or RB chimeras (Figure 1b) . Chimera B-A was constructed by reversing the order of the A and B domains of the RB pocket (Kaelin et al., 1990) leaving the spacer element intact. Chimera A-A represents the substitution of the B domain with another A domain (resulting in a slightly larger protein than wt RB) and, conversely, chimera B-B represents two B domains (smaller than wt RB). In addition to detecting the expected changes in size of the transfected full length RB product, we demonstrated that extracts from H2009 lung cells also contained a smaller 68 kDa species that varied in size according to the predictions of an N-terminal truncation (Figure 1c ). Since the protein band could also be recognized by an antibody raised against a synthetic peptide from the C-terminal end of RB, this suggested again that the truncation occurred N-terminal of the RB pocket domain which predicted that p68 may retain functional pocket binding activity in vivo. To address this issue, we took duplicate protein lysates obtained following transfections with the parental plasmid, wildtype RB, and the 706F mutant RB (Figure 1c , lanes 1 ± 3, respectively) and subjected them ®rst to immunoprecipitation using an a-E2F1 antibody. The washed pellets were then analysed by immunoblot analysis with a-RB (Figure 1d ). We observed that the 68 kDa species from wildtype RB could bind E2F1 in vivo, while the corresponding band from the 706F mutant could not. This observation con®rmed that both the full-length and the p68 RB proteins retained the`pocket' motif which is sensitive to the 706F cysteine to phenylalanine substitution (Kaye et al., 1990) .
Apoptosis is associated with cleavage of a 5 kDa fragment from the C-terminus of RB We were, therefore, interested in a recent report that had also identi®ed a truncated p68 RB species by immunoblot analysis and which had suggested that this smaller protein resulted from an N-terminal cleavage during drug induced apoptosis in the HL60 cell line (Bing and Dou, 1996) . Using commercially available a-RB antibodies directed against non-overlapping epitopes, however, we have demonstrated instead that this N-terminal processing was not dependent on drug induced apoptosis. In contrast, treatment of HL60 cells with etoposide resulted in the cleavage of a single 5 kDa fragment from the C-terminal end of both fulllength (p110) and the p68 RB species which coincided with the onset of apoptosis. We incubated HL60 cells in vivo with 30 mM etoposide for 1, 2, 3, 4 and 7 h and observed characteristic morphologic changes (data not shown) and a speci®c pattern of DNA fragmentation associated with apoptosis that occurred abruptly at 3 h ( Figure 2a ). Identical protein extracts from HL60 cells treated for 1 through 6 h with 30 mM etoposide were then subjected to immunoblot analyses using a-RB antibodies directed against either: (i) the N-terminal domain (`ab-N term'; RB residues 300 ± 380; PharMingen, no. G3-245): (ii) a region spanning the A domain (`ab-A dom'; RB residues 443 ± 622, PharMingen, no. XZ55); and (iii) the C-terminal end (`ab-C term'; carboxyl terminal residues 914 ± 928, Santa Cruz Biotechnology, no. sc-50). All three antibodies can detect both hypo-and hyperphosphorylated RB, although`ab-A dom' has been observed to react weakly with maximally phosphorylated RB species. Immunoblot analysis of lung cancer cell lines H1466 and H292 using a-RB (`ab-N term') was performed as previously published (Kaye et al., 1990) . Protein size markers (Life Sciences, Gaithersburg, MD) are depicted on the left. The H1466 and H292 lung cancer cell lines were generated at the NCI-Navy Oncology Branch and were propagated in RPMI supplemented with 10% FBS as previously published (Carney et al., 1985; Shimizu et al., 1994) . ( were ®rst immunoprecipitated with a-E2F1 followed by immunoblot analysis with a-RB as previously published (Kaye et al., 1990) Using the`ab-N term' antibody, we demonstrated that following 3 h of etoposide treatment the p110 and p68 RB species shifted to a faster migrating p100 and p63 species that we have designated as p100-cleaved (p100cl) and p63cl, respectively (Figure 2b) . Similarly, using`ab-A dom' we also observed a shift to p100cl and p63cl following 3 h exposure to etoposide, although the p68 species is recognized poorly by this antibody (Figure 2c ). In addition, another signal is detected with the`ab-A dom' antibody at approximately 48 kDa which also shifts following 3 h of drug exposure to a band designated as p43cl. Immunoblot analysis of duplicate protein extracts using the Cterminal a-RB antibody (`ab-C term'), however, shows a distinct pattern. Only decreasing amounts of the larger p110, p68 and p48 signals are detected, suggesting that a fragment from each RB species is cleaved at 3 h removing the C-terminal immunogenic epitope that this antibody was raised against ( Figure  2d ). This hypothesis is con®rmed by the detection of large amount of a 5 kDa fragment that is detectable only with the`ab-C term' antibody after 3 h of etoposide treatment (Figure 2e ). The same results were obtained following exposure of HL60 cells to a dierent cytotoxic agent, cytosine arabinoside, instead of etoposide (Figure 2f ). . Protein extracts from HL60 cells treated with 30 mM etoposide for 1 ± 6 h were ®rst immunoprecipitated and then subjected to immunoblotting using (b) an a-RB antibody directed at an epitope from the N-terminal region of RB (`ab-N term') (c) an a-RB antibody directed at an epitope from the A domain region of the RB pocket (`ab-A dom') or (d) an a-RB antibody directed at an epitope from the C-terminal region of RB (`ab-C term'). (e) extracts from HL60 cells treated for 0, 1.5 or 3 h of etoposide were separated by high percent (15%) SDS ± PAGE and immunoblotted using the a-RB antibody directed against the C-terminal region of RB (`ab-C term'). (f) HL60 cells treated with 40 mM cytosine arabinoside (Sigma) for 1 ± 5 h were subjected to sequential immunoprecipitation and immunoblotting with`ab-N term'. Protein size markers are depicted on the left of each panel. Nomenclature for the cleaved (cl) RB protein species is shown on the right. IgH represents the migration of heavy chain immunoglobulin used for the immunoprecipitations p100cl is distinct from dephosphorylated RB To con®rm that the 5 kDa shift in size detected following drug treatment was not due to changes in mobility associated with dephosphorylation, we subjected protein lysates from HL60 cell treated with etoposide for 1.5 or 4 h with potato acid phosphatase (PAP) followed by immunoblotting with the a-RB (`ab-N term') ( Figure 3a) . We observed the collapse of the broad-based p110 signal into a discrete band depicting hypophosphorylated RB (hypo p110) as previously described (Ludlow et al., 1993) . In addition, we noted that the broad p68 signal also was reduced to a single band by PAP consistent with dephosphorylated p68 (hypo p68). Both hypo p110 and hypo p68, however, could be easily discriminated from the apoptosis-linked cleavage products (p100cl and p63cl) observed after 4 h of etoposide treatment (Figure 3a , lanes 4 ± 6). ± 3) or 4 h (lanes 4 ± 6) were subjected to immunoprecipitation with`ab-N term' and the washed pellets were preincubated with phosphate buer alone (lanes 2 and 5) or with 3 mg potato acid phosphatase (PAP) followed by immunoblotting with`ab-N term'. The protocol for potato acid phosphatase (PAP) treatment was modi®ed from previous studies (Cooper and King, 1986) and was generously provided by J Horowitz. a-RB immunoprecipitates were incubated for 20 min at 308C with 3 mg of potato acid phosphatase (PAP; Boehringer Mannheim, Indianapolis, IN) in 45 ml of 40 mM PIPES pH 6.0, 1 mM DTT, 1 mM PMSF, 5 mg/ml of leupeptin, aprotinin, and antipain and 0.5 mg/ml pepstatin. The pellets were washed again, boiled in loading buer, and subjected to SDS ± PAGE and immunoblotting as described above. (b) HL60 cells were incubated with 30 mM etoposide for 0 h (lane 1) or 4 h (lanes 2 and 3) in the absence (lane 2) or presence (lane 3) of 10 mM iodoacetamide (IAA, Sigma) prior to harvesting for protein extracts and immunoblotting with the`ab-A dom' antibody. Subcon¯uent MCF10 cells were incubated with 1 mg/ml cycloheximide and 1 mg/ml a-FAS monoclonal antibody for 0, 1.5, 4 or 7 h and (c) genomic DNA was isolated and subjected to agarose electrophoresis and (d) protein extract was harvested and subjected to sequential immunoprecipitation and immunoblotting with either`ab-N' or`ab-C' as depicted. The a-FAS monoclonal antibody was obtained from Upstate Biotechnology Incorporated, Lake Placid, NY. HL60 promyelocytic cells and MCF10 breast epithelial cells were obtained from the American Type Culture Collection and were propagated in culture as recommended by the supplier Cleavage site maps to a conserved CPP32 recognition sequence at the C-terminus of RB Since apoptosis is associated with the activation of a family of related cysteine proteases (Fraser and Evan, 1996; Martin and Green, 1995) , we examined whether this cleavage event could be inhibited by iodoacetamide; a speci®c cysteine alkylating reagent. Treatment of HL60 cells with iodoacetamide (IAA) prevented apoptosis (data not shown) and inhibited the cleavage of the p110 and p68 when added to the cell media prior to the onset of drug induced apoptosis (Figure 3b) . The routine addition of 50 mM iodoacetamide to the protein extraction buer, however, had no eect on inhibiting RB cleavage.
To address whether RB could serve as a substrate for a cysteine protease in other models of apoptosis, we harvested protein extracts from a non-transformed breast epithelial cell line (designated MCF10), that can be induced to undergo apoptosis following the in vivo exposure to a-FAS (Nagata and Golstein, 1995) ( Figure 3c ). Although only full-length p110 RB (and no p68 protein) is detected in untreated MCF10 breast cells, we again observed the same C-terminal cleavage of p110 RB to p100cl that coincided with the onset of FAS-induced apoptosis. As expected, this resulted again in a truncated protein that could no longer be detected with the`ab-C term' antibody ( Figure 3d) . Inspection of the amino aid sequence for human RB con®rmed that a single consensus CED3/CPP32b-like cleavage site, DEAD G (Nicholson et al., 1995; Wang et al., 1996) was located 42 residues from the carboxyl terminus of human, rat, chicken and xenopus RB (Figure 3e ), but was not present in the rest of the RB open reading frame nor in either of the related RB proteins, p107 or p130 (Ewen et al., 1991; Hannon et al., 1993; Mayol et al., 1993) , which do not undergo cleavage during apoptosis (data not shown).
p100cl and p63cl show enhanced binding to E2F family members
Since both the p110 and p68 products retain the ability to be precipitated by an a-E2F1 antibody in vivo ( Figure  1d , lane 2), we examined the functional ability of p100cl and p63cl to bind E2F family members in vivo. We initially immunoprecipitated untreated or drug treated HL60 cells with a mixture of all three speci®c a-RB antibodies followed by immunoblotting again with each antibody separately (Figure 4a ). This experiment again con®rmed that`ab-C term' cannot recognize the cleaved p100cl and p63cl species. We then subjected these same lysates to immunoprecipitation with an a-E2F1 antibody followed by immunoblotting with each of the three a-RB antibodies separately. We observed enhanced binding of E2F1 with the cleaved RB species (Figure 4b , lanes 1 ± 6) and, as predicted, we detected markedly reduced E2F1 binding using the`ab-C term' antibody which cannot recognize the cleaved RB products (Figure 4b, lane 9) . Although this increased binding may be due to a shift toward dephosphorylation, we have observed both hyper and hypo-phosphorylated species of the p100cl (data not shown). In addition, we also observed enhanced binding of p100cl with E2F3 and E2F4 (Figures 4c and d) .
These ®ndings raise several important points. First, we have demonstrated that RB serves as a substrate for (a) HL60 cells were incubated with 30 mM etoposide for either 0, 1.5 or 4 h and the protein extracts from each drug treatment were immunoprecipitated with a cocktail of all three a-RB antibodies (`ab-N term',`ab-A dom', and`ab-C term'). The washed pellets were then subjected to immunoblotting with each antibody separately. (b) An aliquot of the protein extracts from a was immunoprecipitated with a-E2F1 followed by immunoblotting with the three a-RB antibodies as shown. An aliquot of the protein extracts from a was (c) subjected to immunoprecipitation with either a-E2F1, a-E2F3, a-E2F4 or a-E2F5 followed by immunoblotting with`ab-N term' or (d) subjected to immunoblotting directly with a-E2F1, a-E2F3, a-E2F4 or a-E2F5. HL60 cells did not contain detectable levels of E2F5 protein. The a-E2F1 (cat no. sc-193), a-E2F3 no. sc-878), a-E2F4 no. 866), and a-E2F5 no. sc-999) antibodies were obtained from Santa Cruz Biotechnology, Santa Cruz, CA a CED3-like cysteine protease during both receptor (a-FAS) and non-receptor (DNA damage) mediated apoptosis. In addition, this cleavage event occurs in cells that contain either wildtype or mutant p53. This results in a subtle shift in protein mobility from p110 to p100cl that was previously inferred to represent RB dephosphorylation, but which we have now shown to represent a cleavage event that we have mapped to a unique CPP32 recognition sequence located 42 residues from the C-terminus of RB. In addition, both p100cl and the 5 kDa C-terminal fragment are stable and can be readily detected at the onset of apoptosis. RB, therefore, belongs to a growing list of nuclear proteins that may serve as substrates for activated cysteine proteases (Fraser and Evan, 1996; Martin and Green, 1995) . We have also observed that protein extracts from selected tumor cell lines may also contain a smaller RB-speci®c species (designated p68) that retains the full-length properties of dierential phosphorylation and which encodes an E2F binding domain with potential tumor suppressor activity (Goodrich and Lee, 1992; Qin et al., 1992; Xu et al., 1994) . Although we cannot exclude the possibility that the appearance of the p68 product may arise through limited proteolysis during protein extraction, we observed that the expression of p68 was independent of apoptosis, was not inhibited by the addition of protease inhibitors to the extraction buer, and appeared to be cell line speci®c. The critical question, therefore, involves the timing of the C-terminal cleavage event with respect to the initiation of drug induced or Fas induced apoptosis. For example, is the cleavage of RB a late event that re¯ects the promiscuous activity of activated cysteine proteases in cells irreversibly committed to programmed cell death or does it play an early biological role in this process. Functional experiments testing cleaved and uncleavable forms of RB in both RB(+) and RB(7) cells will be helpful in addressing this issue. While the causality for this cleavage event in the apoptotic process is still under investigation, our ®ndings suggest distinct post-translational pathways for the RB product between cells examined during either growth arrest (p105 hypoRB) or apoptosis (p100cl).
Note added in proof
Similar data demonstrating C-terminal cleavage of RB during apoptosis was published (Janicke et al., 1996) while this manuscript was under review.
